Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1349949

Cover Image

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1349949

Pulmonary Drug Delivery Systems Market, By Product type, By Application, By Distribution Channel, By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

PUBLISHED:
PAGES: 233 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF (Single User License)
USD 4500
PDF (Multi User License)
USD 7000
PDF (Enterprise User License)
USD 10000

Add to Cart

The global pulmonary drug delivery systems market is estimated to be valued at US$ 34.34 billion in 2023 and is expected to exhibit a CAGR of 4.6% during the forecast period (2023-2030).

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 34.34 Bn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 4.60% 2030 Value Projection: US$ 47.05 Bn
Pulmonary Drug Delivery Systems Market - IMG1

Pulmonary drug delivery is a route of administration in which patients use an inhaler to inhale its medications, and drugs are absorbed into the bloodstream via the lung mucous membrane. It provides direct access to disease in the treatment of respiratory diseases, while providing an enormous surface area and a relatively low enzymatic, controlled environment for systemic absorption of medications.

Pulmonary drug delivery offers several advantages as a route of administration for the treatment of systemic diseases compared with intravenous, oral, buccal, transdermal, vaginal, nasal or ocular administration.

Market Dynamics

The key market players are focused on organic growth strategies such as product approval by regulatory authorities to expand its product portfolio is expected to drive the global pulmonary drug delivery systems market growth over the forecast period. For instance, in July 2020, Novartis AG, a pharmaceutical company, announced that the European Commission (EC) has approved Enerzair Breezhaler, as a maintenance treatment of asthma in adult patients. The approval also includes an optional digital companion with sensor and app that provides inhalation confirmation, medication reminders and access to objective data to better support therapeutic decisions.

The increasing research and development activities by key market players for the treatment of pulmonary diseases is expected to drive the market growth over the forecast period. For instance, in December 2020, Intas Pharmaceuticals Ltd., announced that the company was focused on developing advanced inhalation formulation having fundamental advantages in the therapy of diseases of the respiratory tract, including asthma and Chronic Obstructive Pulmonary Disease with Orally Disintegrating Tablet Technology. The Drug delivery system designed for rapid disintegration of the product ensuring faster onset of action. This technology is used for several molecules to facilitate ease of administration and improved patient compliance & convenient dosing for paediatric, geriatric, and psychiatric patients with respiratory diseases.

Key features of the study:

  • This report provides an in-depth analysis of the global pulmonary drug delivery systems market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global pulmonary drug delivery systems marketbased on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include 3M Health Care, Allied Healthcare Products, Inc., AstraZeneca, Boehringer Ingelheim International GmbH., CareFusion Corporation, GF Health Products, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Omron Healthcare, Inc., Glenmark Pharmaceuticals, PARI Respiratory Equipment, Inc., and Koninklijke Philips N.V.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global pulmonary drug delivery systems market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pulmonary drug delivery systems market

Detailed Segmentation:

  • Global Pulmonary Drug Delivery Systems Market, By Product Type:
    • Nebulizers
    • Dry Powder Inhalers (DPIs)
    • Metered Dose Inhalers (MDIs)
  • Global Pulmonary Drug Delivery Systems Market, By Application:
    • Asthma
    • Chronic Obstructive Pulmonary Disease (COPD)
    • Cystic Fibrosis
    • Allergic Rhinitis
    • Others
  • Global Pulmonary Drug Delivery Systems Market, By Distribution Channel:
    • Hospitals Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Pulmonary Drug Delivery Systems Market, By Region:
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • Central Africa
    • North Africa
  • Company Profiles
    • 3M Health Care
    • Allied Healthcare Products, Inc.
    • straZeneca
    • Boehringer Ingelheim International GmbH.
    • CareFusion Corporation
    • GF Health Products, Inc.
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • Novartis AG
    • Omron Healthcare, Inc.
    • Glenmark Pharmaceuticals
    • PARI Respiratory Equipment, Inc.
    • Koninklijke Philips N.V.
Product Code: CMI3952

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Product Type
    • Market Snapshot, By Application
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Recent Product Launches
  • Epidemiology
  • Merger, Acquisition, and Collaborations
  • Regulatory Scenario
  • Key Developments
  • PEST Analysis
  • Partnership Scenario
  • Brand and Pricing Analysis
  • Distributors Landscape
  • Porters Analysis
  • Technological Advancements
  • Key Developments
  • Market Trend

4. Global Pulmonary Drug Delivery Systems Market- COVID-19 Impact Analysis

  • Economic Impact
  • COVID-19 Epidemiology
  • Impact on Supply and Demand

5. Global Pulmonary Drug Delivery Systems Market, By Product Type, 2018-2030, (US$ Million)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Nebulizers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
    • Segment Trends
  • Dry Powder Inhalers (DPIs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
    • Segment Trends
  • Metered Dose Inhalers (MDIs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
    • Segment Trends
    • Segment Trends

6. Global Pulmonary Drug Delivery Systems Market, By Application, 2018-2030, (US$ Million)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Asthma
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
    • Segment Trends
  • Chronic Obstructive Pulmonary Disease (COPD)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
    • Segment Trends
  • Cystic Fibrosis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
    • Segment Trends
  • Allergic Rhinitis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
    • Segment Trends
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
    • Segment Trends

7. Global Pulmonary Drug Delivery Systems Market, By Distribution Channel, 2018-2030, (US$ Million)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Hospitals Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)

8. Global Pulmonary Drug Delivery Systems Market, By Region, 2018-2030, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, For Regions, 2018-2030
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product type, 2018-2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Million)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product type, 2018-2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Modality, 2018-2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Million)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product type, 2018-2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Million)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product type, 2018-2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Million)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product type, 2018-2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Million)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product type, 2018-2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Million)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

  • 3M Health Care
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Allied Healthcare Products, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • AstraZeneca
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Boehringer Ingelheim International GmbH.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • CareFusion Corporation
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • GF Health Products, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • GlaxoSmithKline plc
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Merck & Co., Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Omron Healthcare, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Glenmark Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • PARI Respiratory Equipment, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Koninklijke Philips N.V.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies

10. Section

  • Research Methodology
  • About Us
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!